Lung cancer risk test trial: Study design, participant baseline characteristics, bronchoscopy safety, and establishment of a biospecimen repository

E. L. Crawford, A. Levin, F. Safi, M. Lu, A. Baugh, X. Zhang, J. Yeo, S. A. Khuder, A. M. Boulos, P. Nana-Sinkam, P. P. Massion, D. A. Arenberg, David Eric Midthun, P. J. Mazzone, S. D. Nathan, R. Wainz, G. Silvestri, J. Tita, J. C. Willey

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: The Lung Cancer Risk Test (LCRT) trial is a prospective cohort study comparing lung cancer incidence among persons with a positive or negative value for the LCRT, a 15 gene test measured in normal bronchial epithelial cells (NBEC). The purpose of this article is to describe the study design, primary endpoint, and safety; baseline characteristics of enrolled individuals; and establishment of a bio-specimen repository. Methods/Design: Eligible participants were aged 50-90 years, current or former smokers with 20 pack-years or more cigarette smoking history, free of lung cancer, and willing to undergo bronchoscopic brush biopsy for NBEC sample collection. NBEC, peripheral blood samples, baseline CT, and medical and demographic data were collected from each subject. Discussion: Over a two-year span (2010-2012), 403 subjects were enrolled at 12 sites. At baseline 384 subjects remained in study and mean age and smoking history were 62.9years and 50.4 pack-years respectively, with 34% current smokers. Obstructive lung disease (FEV1/FVC

Original languageEnglish (US)
Article number16
JournalBMC Pulmonary Medicine
Volume16
Issue number1
DOIs
StatePublished - Jan 22 2016

Fingerprint

Bronchoscopy
Lung Neoplasms
Safety
Epithelial Cells
Smoking
History
Obstructive Lung Diseases
Cohort Studies
Demography
Prospective Studies
Biopsy
Incidence
Genes

Keywords

  • Bronchial brush safety
  • Bronchoscopy safety
  • Hereditary lung cancer risk
  • Lung cancer risk test
  • Lung cancer screening
  • Normal bronchial epithelial cells

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Lung cancer risk test trial : Study design, participant baseline characteristics, bronchoscopy safety, and establishment of a biospecimen repository. / Crawford, E. L.; Levin, A.; Safi, F.; Lu, M.; Baugh, A.; Zhang, X.; Yeo, J.; Khuder, S. A.; Boulos, A. M.; Nana-Sinkam, P.; Massion, P. P.; Arenberg, D. A.; Midthun, David Eric; Mazzone, P. J.; Nathan, S. D.; Wainz, R.; Silvestri, G.; Tita, J.; Willey, J. C.

In: BMC Pulmonary Medicine, Vol. 16, No. 1, 16, 22.01.2016.

Research output: Contribution to journalArticle

Crawford, EL, Levin, A, Safi, F, Lu, M, Baugh, A, Zhang, X, Yeo, J, Khuder, SA, Boulos, AM, Nana-Sinkam, P, Massion, PP, Arenberg, DA, Midthun, DE, Mazzone, PJ, Nathan, SD, Wainz, R, Silvestri, G, Tita, J & Willey, JC 2016, 'Lung cancer risk test trial: Study design, participant baseline characteristics, bronchoscopy safety, and establishment of a biospecimen repository', BMC Pulmonary Medicine, vol. 16, no. 1, 16. https://doi.org/10.1186/s12890-016-0178-4
Crawford, E. L. ; Levin, A. ; Safi, F. ; Lu, M. ; Baugh, A. ; Zhang, X. ; Yeo, J. ; Khuder, S. A. ; Boulos, A. M. ; Nana-Sinkam, P. ; Massion, P. P. ; Arenberg, D. A. ; Midthun, David Eric ; Mazzone, P. J. ; Nathan, S. D. ; Wainz, R. ; Silvestri, G. ; Tita, J. ; Willey, J. C. / Lung cancer risk test trial : Study design, participant baseline characteristics, bronchoscopy safety, and establishment of a biospecimen repository. In: BMC Pulmonary Medicine. 2016 ; Vol. 16, No. 1.
@article{e32712287b114906b647f6546272ade5,
title = "Lung cancer risk test trial: Study design, participant baseline characteristics, bronchoscopy safety, and establishment of a biospecimen repository",
abstract = "Background: The Lung Cancer Risk Test (LCRT) trial is a prospective cohort study comparing lung cancer incidence among persons with a positive or negative value for the LCRT, a 15 gene test measured in normal bronchial epithelial cells (NBEC). The purpose of this article is to describe the study design, primary endpoint, and safety; baseline characteristics of enrolled individuals; and establishment of a bio-specimen repository. Methods/Design: Eligible participants were aged 50-90 years, current or former smokers with 20 pack-years or more cigarette smoking history, free of lung cancer, and willing to undergo bronchoscopic brush biopsy for NBEC sample collection. NBEC, peripheral blood samples, baseline CT, and medical and demographic data were collected from each subject. Discussion: Over a two-year span (2010-2012), 403 subjects were enrolled at 12 sites. At baseline 384 subjects remained in study and mean age and smoking history were 62.9years and 50.4 pack-years respectively, with 34{\%} current smokers. Obstructive lung disease (FEV1/FVC",
keywords = "Bronchial brush safety, Bronchoscopy safety, Hereditary lung cancer risk, Lung cancer risk test, Lung cancer screening, Normal bronchial epithelial cells",
author = "Crawford, {E. L.} and A. Levin and F. Safi and M. Lu and A. Baugh and X. Zhang and J. Yeo and Khuder, {S. A.} and Boulos, {A. M.} and P. Nana-Sinkam and Massion, {P. P.} and Arenberg, {D. A.} and Midthun, {David Eric} and Mazzone, {P. J.} and Nathan, {S. D.} and R. Wainz and G. Silvestri and J. Tita and Willey, {J. C.}",
year = "2016",
month = "1",
day = "22",
doi = "10.1186/s12890-016-0178-4",
language = "English (US)",
volume = "16",
journal = "BMC Pulmonary Medicine",
issn = "1471-2466",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Lung cancer risk test trial

T2 - Study design, participant baseline characteristics, bronchoscopy safety, and establishment of a biospecimen repository

AU - Crawford, E. L.

AU - Levin, A.

AU - Safi, F.

AU - Lu, M.

AU - Baugh, A.

AU - Zhang, X.

AU - Yeo, J.

AU - Khuder, S. A.

AU - Boulos, A. M.

AU - Nana-Sinkam, P.

AU - Massion, P. P.

AU - Arenberg, D. A.

AU - Midthun, David Eric

AU - Mazzone, P. J.

AU - Nathan, S. D.

AU - Wainz, R.

AU - Silvestri, G.

AU - Tita, J.

AU - Willey, J. C.

PY - 2016/1/22

Y1 - 2016/1/22

N2 - Background: The Lung Cancer Risk Test (LCRT) trial is a prospective cohort study comparing lung cancer incidence among persons with a positive or negative value for the LCRT, a 15 gene test measured in normal bronchial epithelial cells (NBEC). The purpose of this article is to describe the study design, primary endpoint, and safety; baseline characteristics of enrolled individuals; and establishment of a bio-specimen repository. Methods/Design: Eligible participants were aged 50-90 years, current or former smokers with 20 pack-years or more cigarette smoking history, free of lung cancer, and willing to undergo bronchoscopic brush biopsy for NBEC sample collection. NBEC, peripheral blood samples, baseline CT, and medical and demographic data were collected from each subject. Discussion: Over a two-year span (2010-2012), 403 subjects were enrolled at 12 sites. At baseline 384 subjects remained in study and mean age and smoking history were 62.9years and 50.4 pack-years respectively, with 34% current smokers. Obstructive lung disease (FEV1/FVC

AB - Background: The Lung Cancer Risk Test (LCRT) trial is a prospective cohort study comparing lung cancer incidence among persons with a positive or negative value for the LCRT, a 15 gene test measured in normal bronchial epithelial cells (NBEC). The purpose of this article is to describe the study design, primary endpoint, and safety; baseline characteristics of enrolled individuals; and establishment of a bio-specimen repository. Methods/Design: Eligible participants were aged 50-90 years, current or former smokers with 20 pack-years or more cigarette smoking history, free of lung cancer, and willing to undergo bronchoscopic brush biopsy for NBEC sample collection. NBEC, peripheral blood samples, baseline CT, and medical and demographic data were collected from each subject. Discussion: Over a two-year span (2010-2012), 403 subjects were enrolled at 12 sites. At baseline 384 subjects remained in study and mean age and smoking history were 62.9years and 50.4 pack-years respectively, with 34% current smokers. Obstructive lung disease (FEV1/FVC

KW - Bronchial brush safety

KW - Bronchoscopy safety

KW - Hereditary lung cancer risk

KW - Lung cancer risk test

KW - Lung cancer screening

KW - Normal bronchial epithelial cells

UR - http://www.scopus.com/inward/record.url?scp=84955335517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955335517&partnerID=8YFLogxK

U2 - 10.1186/s12890-016-0178-4

DO - 10.1186/s12890-016-0178-4

M3 - Article

C2 - 26801409

AN - SCOPUS:84955335517

VL - 16

JO - BMC Pulmonary Medicine

JF - BMC Pulmonary Medicine

SN - 1471-2466

IS - 1

M1 - 16

ER -